Other Rheumatic and Connective Tissue Disorders

Dana R., 43, an elementary school music teacher, has early diffuse cutaneous systemic sclerosis and a narrowing window in which stem-cell transplant eligibility still applies. The disagreement is whether the SCOT trial's real but qualified survival benefit justifies a treatment this intense before her disease has had time to declare how bad it will get.

Marisol T., 52, a ceramic artist, has digital ulcers from systemic sclerosis that keep recurring despite standard care. The disagreement turns out to hinge on a distinction the trials themselves don't blur: an endothelin antagonist proven to prevent new ulcers is not the same thing as a drug proven to heal the one she has right now.

Linda F., 58, who helps raise her grandchildren several afternoons a week, has Sjögren's disease newly involving her kidneys and skin. The disagreement is whether to reach for rituximab's actual track record or a newer B-cell agent whose trial data looks better on paper but hasn't been tested in a patient quite like her.

Rita A., 61, a hospital pharmacist close to retirement, has dermatomyositis skin disease that hasn't responded even though her muscle disease is controlled. The disagreement is which trial's patients she actually resembles — because the two drugs on the table were proven in populations that don't look like her at all.

Walt H., 67, who still climbs ladders most mornings during harvest, developed anti-HMGCR myopathy from a statin and has been off it and in remission for months. The disagreement is whether restarting a statin is ever defensible again, or whether a PCSK9 inhibitor should simply take the job over for good.

George K., 71, has spent thirty years at a woodworking bench and is now losing grip strength to inclusion body myositis, a disease with no proven drug therapy. The disagreement is whether a bounded, time-limited immunosuppression trial is worth the real side-effect cost, or whether structured supportive care alone is the more honest offer.

Ana N., 32, raising two children under five, has mixed connective tissue disease flaring in her muscles while her joints and a new pulmonary-pressure finding both need attention too. The disagreement is how to treat the organ that's flaring loudest without quietly under-treating everything else going on at the same time.

Celia B., a voice teacher and former opera singer, has relapsing polychondritis now reaching her airway. The disagreement is which biologic to reach for when the actual evidence behind both options is thin enough that neither side can claim real proof, only a reasonable bet.

Jerome P., 49, a landscaper, has eosinophilic fasciitis that won't let him taper off steroids and new joint contractures forming underneath. The disagreement is which steroid-sparing agent actually has the evidence to justify the switch, once the drugs that sound reasonable are checked against what's really been studied.

Sofia O., 29, newly married and planning a family within the next year or two, has undifferentiated connective tissue disease that hasn't declared itself yet. The disagreement is whether starting hydroxychloroquine now, ahead of a pregnancy that hasn't been conceived, is genuine prevention or treatment without a diagnosis to justify it.

Kara D., 38, a lifelong marathon runner, has antisynthetase syndrome with no lung disease yet — just a skin finding that turns out to be the real warning sign, not the lab value everyone reaches for first. The disagreement is whether that skin finding alone justifies treating her lungs pre-emptively, or whether surveillance can safely wait for real evidence to appear.